Literature DB >> 9499077

Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates.

D Del Mauro1, D Matteucci, S Giannecchini, F Maggi, M Pistello, M Bendinelli.   

Abstract

Feline immunodeficiency virus (FIV) provides a model system with which the significance of neutralizing antibody (NA) in immunosuppressive lentivirus infections may be studied. To date, no detailed analysis of the neutralization properties of primary FIV isolates has been reported. In this study, we have conducted the first comprehensive study of the sensitivity to autologous and heterologous neutralization in a lymphoid cell-based assay of 15 primary FIV isolates and, for comparison, of one tissue culture-adapted strain. Primary isolates in general proved highly NA resistant, although there was considerable individual variation. Variation was also observed in the capacity of immune sera to neutralize heterologous FIV isolates. The ability of sera to neutralize isolates or for isolates to be neutralized by sera did not correlate with epidemiological and genetic relatedness or with the quasispecies complexity of the isolates. From the study of specific-pathogen-free cats experimentally infected with viral isolates associated with NA of different breadths, it appears that the development of FIV vaccines cannot rely on the existence of viral strains inherently capable of inducing especially broad NA responses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9499077      PMCID: PMC109516          DOI: 10.1128/JVI.72.3.2199-2207.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  Monoclonal antibodies to immunodominant and neutralizing domains of the envelope surface protein of feline immunodeficiency virus.

Authors:  H Egberink; L Keldermans; N Schuurman; J Stam; W Hesselink; A van Vliet; E Verschoor; M Horzinek; A de Ronde
Journal:  J Gen Virol       Date:  1994-04       Impact factor: 3.891

2.  Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines.

Authors:  M J Hosie; R Osborne; J K Yamamoto; J C Neil; O Jarrett
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

3.  Neutralization of HIV-1.

Authors:  H Golding; M P D'Souza; J Bradac; B Mathieson; P Fast
Journal:  AIDS Res Hum Retroviruses       Date:  1994-06       Impact factor: 2.205

4.  Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.

Authors:  J P Moore; Y Cao; D D Ho; R A Koup
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

5.  Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion.

Authors:  M L Tsang; L A Evans; P McQueen; L Hurren; C Byrne; R Penny; B Tindall; D A Cooper
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

6.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.

Authors:  Y Cao; L Qin; L Zhang; J Safrit; D D Ho
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

7.  Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus.

Authors:  T Wrin; L Crawford; L Sawyer; P Weber; H W Sheppard; C V Hanson
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-03

8.  Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system.

Authors:  F Baldinotti; D Matteucci; P Mazzetti; C Giannelli; P Bandecchi; F Tozzini; M Bendinelli
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  Virus neutralization reveals antigenic variation among feline immunodeficiency virus isolates.

Authors:  R Osborne; M Rigby; K Siebelink; J C Neil; O Jarrett
Journal:  J Gen Virol       Date:  1994-12       Impact factor: 3.891

10.  Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines.

Authors:  K H Siebelink; E Tijhaar; R C Huisman; W Huisman; A de Ronde; I H Darby; M J Francis; G F Rimmelzwaan; A D Osterhaus
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more
  11 in total

1.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies.

Authors:  S Giannecchini; D Del Mauro; D Matteucci; M Bendinelli
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Feline immunodeficiency virus-infected cat sera associated with the development of broad neutralization resistance in vivo drive similar reversions in vitro.

Authors:  S Giannecchini; D Matteucci; A Ferrari; M Pistello; M Bendinelli
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

3.  During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein.

Authors:  M Bendinelli; M Pistello; D Del Mauro; G Cammarota; F Maggi; A Leonildi; S Giannecchini; C Bergamini; D Matteucci
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

4.  AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens.

Authors:  Mauro Pistello; Francesca Bonci; J Norman Flynn; Paola Mazzetti; Patrizia Isola; Elisa Zabogli; Valentina Camerini; Donatella Matteucci; Giulia Freer; Paolo Pelosi; Mauro Bendinelli
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

5.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Authors:  Mauro Pistello; Donatella Matteucci; Francesca Bonci; Patrizia Isola; Paola Mazzetti; Lucia Zaccaro; Antonio Merico; Daniela Del Mauro; Norman Flynn; Mauro Bendinelli
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats.

Authors:  M Pistello; D Matteucci; G Cammarota; P Mazzetti; S Giannecchini; D Del Mauro; S Macchi; L Zaccaro; M Bendinelli
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

7.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine.

Authors:  P Mazzetti; S Giannecchini; D Del Mauro; D Matteucci; P Portincasa; A Merico; C Chezzi; M Bendinelli
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 8.  Feline immunodeficiency virus neuropathogenesis: from cats to calcium.

Authors:  Rick B Meeker
Journal:  J Neuroimmune Pharmacol       Date:  2006-11-28       Impact factor: 4.147

9.  Role of Env in resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV strain as determined by using a chimeric virus.

Authors:  Simone Giannecchini; Mauro Pistello; Patrizia Isola; Donatella Matteucci; Paola Mazzetti; Giulia Freer; Mauro Bendinelli
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

10.  Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.

Authors:  Simone Giannecchini; Armida Di Fenza; Anna Maria D'Ursi; Donatella Matteucci; Paolo Rovero; Mauro Bendinelli
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.